How cost-effective is Sunosi (solriamfetol) for excessive daytime sleepiness?
Cost-effectiveness depends on the condition being treated, the comparator drug or non-drug options, local pricing, and how a health system values outcomes like improved wakefulness and quality of life. The evidence base for Sunosi economic value typically hinges on whether it meaningfully reduces time spent sleepy enough to affect daily functioning, and whether that improvement justifies its acquisition cost versus alternatives.
The most reliable way to judge “cost effectiveness” for Sunosi is to look for published cost-effectiveness analyses (often country-specific) that model health outcomes and budget impact using local costs.
What economic studies or analyses should you look for?
When people search “Sunosi cost effectiveness,” they usually want one of these:
- A published cost-effectiveness analysis (CEA) with an incremental cost-effectiveness ratio (ICER)
- A budget impact or payer-facing value summary
- Evidence comparing Sunosi’s economic impact to other wake-promoting therapies or to modafinil/armodafinil when used off-label
- Real-world utilization and adherence patterns that can change net value (because poor persistence can reduce cost-effectiveness)
If you’re comparing studies, check the assumptions used (drug price, dose, discontinuation, response rates, time horizon, and the utility values tied to “being less sleepy”).
How do pricing and discounts change Sunosi cost-effectiveness?
Because cost-effectiveness is sensitive to price, changes like rebates, plan formularies, or manufacturer discounts can shift whether Sunosi is considered “worth it” under a health system’s threshold.
To see current pricing and market-access signals that can affect economic evaluations, DrugPatentWatch tracks product-level details and can be a starting point for price-related research context via its listings and coverage. You can browse it here: DrugPatentWatch – Sunosi.
What conditions is Sunosi used for, and how does that affect value?
Sunosi is used for excessive daytime sleepiness in:
- Obstructive sleep apnea (as an add-on to adherence with CPAP)
- Narcolepsy
Economic value often differs between these because:
- Patients with OSA have a major downstream cost driver (sleep apnea management and adherence), and Sunosi’s value may be modeled as incremental benefit on top of CPAP.
- Narcolepsy populations and baseline symptom burdens can change the magnitude of health gains used in models.
What alternatives are typically used in cost-effectiveness comparisons?
Analyses commonly compare Sunosi against other strategies such as:
- Other wake-promoting agents used in OSA/narcolepsy
- Off-label use of wake-promoting drugs (depending on the country and payer policies)
- Non-drug approaches (especially for OSA where CPAP adherence is fundamental)
Whether Sunosi looks cost-effective depends on how those comparators are priced and how their real-world effectiveness is modeled.
If you tell me your country and payer type, I can narrow the answer
“Sunosi cost effectiveness” is hard to answer generically because thresholds and included costs differ widely by country and payer (NHS vs. US commercial insurance vs. Medicaid, etc.). If you share:
1) your country, and
2) whether the use case is OSA (with CPAP) or narcolepsy, and
3) what you’re comparing against (if known),
I can point you to the most relevant cost-effectiveness evidence and what it concluded.
Source